Kyongbo Pharmaceutical
경보제약 · 214390
Health Care Pharmaceuticals · KOSPI
Market cap US$95.5M (₩131.7B)
Overview
Kyongbo Pharmaceutical makes active pharmaceutical ingredients, the raw chemical compounds that go into finished medicines, as well as finished prescription and over-the-counter drugs, with cephalosporin antibiotics (a widely used antibiotic family) among its best-known products.
It supplies domestic drug makers and hospitals, and also exports its active ingredients to markets in developed countries. Listed on KOSPI, Korea's main stock exchange, the company operates two roughly equal revenue streams: bulk active ingredients and finished dosage-form medicines, complemented by smaller medical-device and animal-health businesses.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$156.8M
- FY2024US$172.9M
- FY2025US$191.4M
Operating profit
- FY2023US$4M
- FY2024US$7.6M
- FY2025US$2.5M
Net income
- FY2023US$2.2M
- FY2024US$3.4M
- FY2025US$132.1K
Key ratios (FY2025)
Why it matters
The company is developing its own conjugation and payload-linker technologies to enter the global contract development and manufacturing market for antibody-drug conjugate cancer therapies.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?